Mantle cell lymphoma (MCL) is a B-cell malignancy with unique biological, pathological and clinical features, which comprises approximately 3–10% of all non-Hodgkin lymphomas (NHLs) (Swerdlow et al, 2008).
This guideline discusses the investigation and management of patients with mantle cell lymphoma including diagnosis.
Prognostic scores: First line management with emphasis on the different approach for younger, fitter (transplant candidate) patients and watch and wait option for those with asymptomatic, indolent disease.
Second line therapy and beyond
Role of transplantation.
The section on diagnosis of mantle cell lymphoma, should be considered supplementary to the BSH Guideline: Best Practice in Lymphoma Diagnosis and Reporting (Parker et al, 2010).
Declaration of Interests
The BSH paid the expenses incurred during the writing of this guidance. None of the authors had conflicts of interest to declare. All authors have made a declaration of interests to the BSH and Task Force Chairs which may be viewed on request.